Table 6.
Logistic regression analyses for target lesion revascularization at 15 months
| Variable | Target lesion revascularization at 15 months | |||
|---|---|---|---|---|
|
| ||||
| Absent (n=24) | Present (n=6) | OR (crude) (95% CI) | P-value | |
| Age, years | 69.2±9.2 | 72.0±7.5 | 1.04 (0.93-1.16) | 0.49 |
| Male, n (%) | 17 (71) | 3 (50) | 0.41 (0.07-2.56) | 0.34 |
| Diabetes mellitus, n (%) | 10 (42) | 4 (67) | 2.80 (0.43-18.4) | 0.28 |
| Hypertension, n (%) | 23 (96) | 6 (100) | - | - |
| Dyslipidemia, n (%) | 23 (96) | 5 (83) | 0.22 (0.01-4.09) | 0.31 |
| Chronic kidney disease, n (%) | 12 (50) | 4 (67) | 2.00 (0.31-13.1) | 0.47 |
| Current smoker, n (%) | 3 (13) | 2 (33) | 3.50 (0.44-28.1) | 0.24 |
| Family history of coronary artery disease, n (%) | 5 (21) | 0 | - | - |
| History of PCI or CABG, n (%) | 14 (58) | 4 (67) | 1.43 (0.22-9.38) | 0.71 |
| History of cerebral infarction or carotid artery stenosis, n (%) | 9 (38) | 3 (50) | 1.67 (0.28-10.1) | 0.58 |
| Oral medication on admission, n (%) | ||||
| Prior aspirin use | 24 (100) | 6 (100) | - | - |
| Prior clopidogrel use | 21 (88) | 4 (66) | 0.29 (0.04-2.30) | 0.24 |
| Prior prasugrel use | 2 (8) | 2 (33) | 5.50 (0.59-51.2) | 0.134 |
| Prior beta blocker use | 14 (58) | 2 (33) | 0.36 (0.05-2.34) | 0.28 |
| Prior ACEI or ARB | 16 (67) | 3 (50) | 0.50 (0.08-3.06) | 0.45 |
| Prior statin use | 21 (88) | 5 (83) | 0.71 (0.06-8.40) | 0.79 |
| Laboratory tests | ||||
| Hemoglobin, g/dL | 12.9±1.5 | 12.1±1.7 | 0.70 (0.39-1.25) | 0.23 |
| White blood cell count, /μL | 6,100 (5,150-7,250) | 5,600 (4,200-6,300) | 1.00 (1.00-1.00) | 0.58 |
| CRP, mg/dL | 0.10 (0.04-0.16) | 0.14 (0.03-0.29) | 1.11 (0.43-2.87) | 0.83 |
| Total protein, g/dL | 7.1 (6.7-7.4) | 7.0 (6.8-7.1) | 0.34 (0.05-2.26) | 0.26 |
| Albumin, g/dL | 4.2 (4.0-4.4) | 4.3 (4.1-4.4) | 0.63 (0.12-3.45) | 0.60 |
| Creatinine, mg/dL | 0.95 (0.83-1.09) | 0.93 (0.85-4.38) | 1.10 (0.74-1.63) | 0.65 |
| eGFR, mL/min | 53.0±21.4 | 42.2±25.9 | 0.98 (0.94-1.02) | 0.29 |
| Uric acid, mg/dL | 5.2±1.3 | 4.5±1.6 | 0.67 (0.32-1.40) | 0.28 |
| Calcium, mg/dL | 9.3±0.5 | 9.4±0.4 | 2.45 (0.34-17.9) | 0.38 |
| LDL-C, mg/dL | 78 (62-94) | 87 (75-110) | 1.02 (0.98-1.06) | 0.28 |
| Triglyceride, mg/dL | 113 (78-173) | 91 (76-118) | 0.99 (0.97-1.00) | 0.36 |
| Glucose, mg/dL | 119 (109-132) | 113 (108-142) | 1.02 (0.99-1.04) | 0.26 |
| HbA1c, % | 6.1 (5.8-6.8) | 6.7 (5.5-7.2) | 1.88 (0.64-5.57) | 0.25 |
| IL-6, pg/mL | 3.0 (1.9-4.6) | 2.6 (1.3-5.3) | 1.03 (0.90-1.18) | 0.69 |
| TNF-α, pg/mL | 1.14 (0.85-1.55) | 1.38 (1.01-1.56) | 1.75 (0.46-6.74) | 0.41 |
| hs-CRP, ng/mL | 623 (327-1340) | 1044 (534-2300) | 1.00 (1.00-1.00) | 0.92 |
| Pentraxin 3, ng/mL | 1.91 (1.31-2.41) | 2.47 (1.67-2.63) | 1.12 (0.61-2.05) | 0.37 |
| VEGF >20 pg/mL, n (%) | 5 (21) | 2 (33) | 1.90 (0.27-13.5) | 0.52 |
| MCP-1, pg/mL | 182 (149-206) | 227 (211-287) | 1.02 (1.00-1.03) | 0.061 |
| Target lesion, n (%) | ||||
| Left anterior descending artery | 14 (58) | 5 (83) | 3.57 (0.36-35.5) | 0.28 |
| Left circumflex artery | 3 (13) | 0 | - | - |
| Right coronary artery | 7 (29) | 1 (17) | 0.49 (0.05-4.94) | 0.54 |
| Balloon angioplasty, n (%) | 24 (100) | 6 (100) | - | - |
| Stent implantation, n (%) | 14 (58) | 3 (50) | 0.71 (0.12-4.30) | 0.71 |
| Drug-coated balloon, n (%) | 10 (42) | 3 (50) | 1.40 (0.23-8.42) | 0.71 |
| Coronary plaque risk score ≥4 | 4 (17) | 4 (67) | 10.0 (1.34-74.5) | 0.025 |
Continuous variables are presented as mean ± standard deviation if normally distributed and median (interquartile range) if not normally distributed. Categorical variables are presented as number of patients (%). CI, confidence interval; OR, odds ratio. PCI, percutaneous coronary intervention; CABG, coronary artery bypass grafting; CI, cerebral infarction; ACEI, angiotensin converting enzyme inhibitor; ARB, angiotensin II receptor blocker; CRP, C-reactive protein; eGFR, estimated glomerular filtration rate; LDL-C, low-density lipoprotein cholesterol; HbA1c, hemoglobin A1c; IL-6, Interleukin-6; TNF-α, tumor necrosis factor-alpha; hs-CRP, high-sensitivity C-reactive protein; VEGF, vascular endothelial growth factor; MCP-1, monocyte chemoattractant protein-1.